Price
Financials
Standalone, Rs crore| Mar 2013 | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 20.29 | 11.05 | 10.01 | 9.26 | 9.06 | 3.17 | 2.30 | 4.35 | 2.77 |
| Expenses | 49.12 | 51.26 | 23.41 | 10.32 | 9.47 | 2.43 | 1.85 | 2.09 | 4.31 |
| Operating Profit | -28.83 | -40.21 | -13.40 | -1.06 | -0.41 | 0.74 | 0.45 | 2.26 | -1.54 |
| OPM % | -142.09% | -363.89% | -133.87% | -11.45% | -4.53% | 23.34% | 19.57% | 51.95% | -55.60% |
| Other Income | 0.09 | -0.34 | 0.00 | 0.00 | 0.00 | -125.45 | 0.00 | -18.75 | 0.00 |
| Interest | -26.86 | -6.86 | 0.16 | 0.13 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 1.26 | 1.16 | 1.10 | 1.08 | 1.02 | 1.24 | 1.21 | 0.02 | 2.45 |
| Profit before tax | -3.14 | -34.85 | -14.66 | -2.27 | -1.55 | -125.95 | -0.76 | -16.51 | -3.99 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -3.14 | -34.85 | -14.66 | -2.27 | -1.55 | -125.96 | -0.76 | -16.51 | -4.00 |
| EPS in Rs | -1.27 | -14.06 | -5.92 | -0.92 | -0.63 | -50.83 | -0.31 | -6.66 | -1.61 |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Jun 2013 15m | Jun 2014 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 155 | 197 | 295 | 370 | 492 | 657 | 730 | 338 | 32 | 13 |
| Expenses | 139 | 171 | 257 | 322 | 425 | 559 | 662 | 379 | 40 | 11 |
| Operating Profit | 16 | 27 | 38 | 49 | 67 | 98 | 69 | -41 | -9 | 2 |
| OPM % | 10% | 13% | 13% | 13% | 14% | 15% | 9% | -12% | -28% | 15% |
| Other Income | 2 | 1 | 2 | 3 | 3 | 3 | -14 | -114 | -127 | -144 |
| Interest | 6 | 7 | 12 | 21 | 26 | 34 | 45 | 1 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 3 | 3 | 4 | 5 | 6 | 5 | 5 |
| Profit before tax | 10 | 19 | 27 | 28 | 41 | 63 | 4 | -162 | -141 | -147 |
| Tax % | 7% | 26% | 32% | 22% | 20% | 22% | 21% | 0% | 0% | |
| Net Profit | 10 | 14 | 18 | 22 | 33 | 49 | 4 | -162 | -141 | -147 |
| EPS in Rs | 1.42 | -65.52 | -56.91 | -59.41 | ||||||
| Dividend Payout % | 0% | 8% | 12% | 10% | 10% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | -39% | -64% | -68% | ||
| Compounded Profit Growth | % | % | % | 94% | ||
| Stock Price CAGR | % | % | % | % | ||
| Return on Equity | % | % | % | % |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Jun 2013 | Jun 2014 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 11 | 11 | 11 | 11 | 11 | 12 | 12 | 12 |
| Reserves | 5 | 24 | 40 | 59 | 95 | 144 | 169 | 6 | -133 |
| Borrowings | 58 | 67 | 120 | 160 | 195 | 258 | 302 | 307 | 307 |
| Other Liabilities | 43 | 29 | 48 | 55 | 59 | 66 | 68 | 117 | 129 |
| Total Liabilities | 114 | 131 | 219 | 285 | 360 | 478 | 551 | 442 | 315 |
| Fixed Assets | 35 | 30 | 34 | 58 | 67 | 81 | 95 | 88 | 83 |
| CWIP | 0 | 0 | 7 | 5 | 10 | 7 | 7 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 11 | 11 | 11 | 11 |
| Other Assets | 79 | 101 | 177 | 221 | 283 | 379 | 438 | 344 | 220 |
| Total Assets | 114 | 131 | 219 | 285 | 360 | 478 | 551 | 442 | 315 |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Jun 2013 | Jun 2014 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -7 | -2 | -16 | 5 | 14 | -5 | 2 | -6 | 2 |
| Cash from Investing Activity | -1 | -1 | -25 | -25 | -30 | -25 | -19 | 0 | -0 |
| Cash from Financing Activity | 9 | 3 | 42 | 21 | 17 | 27 | 16 | 4 | -1 |
| Net Cash Flow | 0 | 0 | 0 | 2 | 2 | -3 | -1 | -2 | 1 |
| Free Cash Flow | -8 | -3 | -29 | -20 | -3 | -20 | -17 | -6 | 1 |
| CFO/OP | -39% | 10% | -20% | 23% | 32% | 2% | 3% | 12% | -21% |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Jun 2013 | Jun 2014 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 119 | 125 | 140 | 141 | 133 | 143 | 163 | 278 | 2,342 |
| Inventory Days | 57 | 58 | 59 | 68 | 67 | 61 | 50 | 68 | 75 |
| Days Payable | 50 | 44 | 41 | 35 | 33 | 29 | 22 | 32 | 434 |
| Cash Conversion Cycle | 127 | 139 | 159 | 174 | 166 | 175 | 191 | 314 | 1,983 |
| Working Capital Days | 110 | 131 | 159 | 164 | 165 | 161 | 174 | 224 | 1,003 |
| ROCE % | 30% | 28% | 25% | 25% | 27% | 14% | -12% | -5% |
Fundamentals
Market Cap₹ Cr.
Current Price₹ 2.88
Book Value₹ -55.8
ROCE-5.36 %
ROE%
Dividend Yield0.00 %
Face Value₹ 5.00
Compounded Sales Growth (TTM)-68%
Compounded Profit Growth (TTM)94%
Standalone figures.
Valuation
P/E, 3-year average14.16x
P/B, 3-year average0.60x
P/E, 5-year average9.24x
P/B, 5-year average0.90x
Profitability
Operating margin (excl. other income)-12.19%
Operating margin (incl. other income)-45.92%
EBITDA margin-743.17%
Pre-tax margin-766.79%
Net profit margin-766.84%
Net margin, latest quarter-379.54%
ROE-162.29%
ROCE-39.89%
ROA-32.68%
ROE, 3-year average-40.77%
ROCE, 3-year average-0.50%
ROA, 3-year average-6.74%
ROE, 5-year average-9.64%
ROCE, 5-year average9.63%
ROA, 5-year average-0.26%
ROIC (approx.)-44.17%
Other income / net worth-609.53%
Growth
Sales growth (latest year)-53.78%
Profit growth (latest year)-4712.78%
Sales CAGR, 3 years-11.80%
Sales CAGR, 5 years2.75%
Sales growth QoQ89.13%
Sales growth YoY (latest quarter)-53.02%
Per share
EPS (TTM)Rs -58.42
EPS (latest year)Rs -65.52
EPS (latest quarter)Rs -6.66
EPS, 3-year averageRs -13.62
EPS, 5-year averageRs -3.03
Book value per shareRs 7.54
Sales per shareRs 7.62
Cash flow per shareRs -2.34
Free cash flow per shareRs 0.40
Dividend per share, 5-year averageRs 1.25
Dividends
Dividend payout, 5-year average9.70%
Efficiency
Asset turnover0.76x
Fixed asset turnover3.83x
Inventory turnover5.53x
Inventory days66 days
Debtor days278 days
Debtors turnover1.31x
Creditor days434 days
Cash conversion cycle1983 days
Working capital days1003 days
Leverage
Total debtRs 307 Cr
Cash and bankRs 0 Cr
Net debtRs 307 Cr
Debt to equity16.44x
Interest coverage-148.25x
Owners' fund to total sources4.22%
Debt to assets69.41%
Cash flow
Cash from Operating Activity (latest year)Rs -6 Cr
Cash from Investing Activity (latest year)Rs 0 Cr
Cash from Financing Activity (latest year)Rs 4 Cr
Net Cash Flow (latest year)Rs -2 Cr
Free cash flow (latest year)Rs 1 Cr
FCFE (approx.: FCF + change in debt)Rs 6 Cr
Statement figures
Net sales (TTM)Rs 19 Cr
Net sales (latest year)Rs 338 Cr
Sales (latest quarter)Rs 4 Cr
Operating profit excl. other income (latest year)Rs -41 Cr
Operating profit (latest quarter)Rs 2 Cr
Other income (TTM)Rs -114 Cr
EBITDA (TTM)Rs -140 Cr
PBDT (TTM)Rs -141 Cr
Profit before tax (TTM)Rs -145 Cr
Net profit (TTM)Rs -145 Cr
Net profit (latest year)Rs -162 Cr
Net profit (latest quarter)Rs -17 Cr
Depreciation (TTM)Rs 3 Cr
Depreciation (latest quarter)Rs 0 Cr
Interest (TTM)Rs 1 Cr
Cost of goods sold (latest year)Rs 305 Cr
Total expenditure (latest year)Rs 379 Cr
Total income (latest year)Rs 224 Cr
Share capitalRs 12 Cr
ReservesRs 6 Cr
Shareholders' fundsRs 19 Cr
Total assetsRs 442 Cr
Net blockRs 88 Cr
InvestmentsRs 11 Cr
ReceivablesRs 257 Cr
InventoryRs 55 Cr
Other liabilitiesRs 117 Cr
Shares outstanding (crore)2.48
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
Not enough price history.
Red flags
F-score 2 of 8| explain | Receivables outrunning sales Receivables grew -21% vs sales -54% in 2014 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Mar 2015Sales ₹3 Cr -69.4% vs Mar 2014.
Net loss ₹4 Cr.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Twilight Litaka Pharma Ltd?
Twilight Litaka Pharma Ltd (506985) has a market capitalisation of Rs Cr. at the close.
What were Twilight Litaka Pharma Ltd's latest quarterly results?
In the Mar 2015 quarter, Twilight Litaka Pharma Ltd sales was Rs 3 Cr (-69.4% vs Mar 2014) with a net loss of Rs 4 Cr.